Comprehensive Analysis of Volatile Biomarkers for Female Fertility by Ong, Stephanie (Author) et al.
Comprehensive Analysis of Volatile Biomarkers for Female Fertility 
 
by 
 
Stephanie Marie Ong 
 
 
 
 
 
A Thesis Presented in Partial Fulfillment 
of the Requirements for the Degree 
Master of Science 
 
 
 
 
 
 
 
 
 
 
Approved April 2018 by the  
Graduate Supervisory Committee: 
 
Barbara Smith, Chair 
Heather Bean 
Christopher Plaisier 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ARIZONA STATE UNIVERSITY 
 
May 2018 
i 
 
ABSTRACT 
One out of ten women has a difficult time getting or staying pregnant in the 
United States. Recent studies have identified aging as one of the key factors attributed to 
a decline in female reproductive health. Existing fertility diagnostic methods do not allow 
for the non-invasive monitoring of hormone levels across time.  In recent years, olfactory 
sensing has emerged as a promising diagnostic tool for its potential for real-time, non-
invasive monitoring.  This technology has been proven promising in the areas of 
oncology, diabetes, and neurological disorders.  Little work, however, has addressed the 
use of olfactory sensing with respect to female fertility.  In this work, we perform a study 
on ten healthy female subjects to determine the volatile signature in biological samples 
across 28 days, correlating to fertility hormones.  Volatile organic compounds (VOCs) 
present in the air above the biological sample, or headspace, were collected by solid 
phase microextraction (SPME), using a 50/30 µm divinylbenzene/carboxen/ 
polydimethylsiloxane (DVB/CAR/PDMS) coated fiber.  Samples were analyzed, using 
comprehensive two-dimensional gas chromatography-time-of-flight mass spectrometry 
(GC×GC-TOFMS). A regression model was used to identify key analytes, corresponding 
to the fertility hormones estrogen and progesterone. Results indicate shifts in volatile 
signatures in biological samples across the 28 days, relevant to hormonal changes.  
Further work includes evaluating metabolic changes in volatile hormone expression as an 
early indicator of declining fertility, so women may one day be able to monitor their 
reproductive health in real-time as they age. 
 
 
 
ii 
 
DEDICATION 
I dedicate this work to my family, especially my parents, Henry and Lina Ong, for 
their unwavering support. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGMENTS 
I would like to acknowledge Vi Nguyen for her support in gas chromatography-
mass spectrometry (GC-MS) testing, and Devika Krishnamurthy for the collection of 
biological samples in this study. I would also like to acknowledge Dr. John Stufken and 
Abigael Nachtsheim for statistical support. A special thanks to Christopher Miranda for 
programming support and Trenton Davis for GC-MS and statistical support. I would also 
like to thank Jarrett Eshima for his help in running biological samples on the GC x GC-
TOFMS. Lastly, I would like to recognize my graduate committee, Dr. Christopher 
Plaisier, Dr. Heather Bean, and especially my advisor, Dr. Barbara Smith, for their 
support and mentorship throughout my graduate studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
TABLE OF CONTENTS 
                                                                                                                                        Page  
LIST OF TABLES .......................................................................................................... vi    
LIST OF FIGURES ......................................................................................................... vii    
CHAPTER  
1 INTRODUCTION/BACKGROUND LITERATURE………………..... 1   
2  METHODOLOGY................................................................................... 4 
  2.1 Sample Collection and Preparation……………………………... 4 
  2.2 Method Optimization………………………………………….... 5 
  2.3 Instrumentation………………………………………………..... 7 
  2.4 Data Alignment and Normalization.……………………………. 8 
  2.5 Data Analysis: Random Forest and PCA……………………….. 10 
  2.6 Data Analysis: Regression Model and Lasso Technique……….. 10 
  2.7 Data Analysis: t-test and Heat Map ……………………….......... 11 
  2.8 Compound Validation and Quality of Data……………………... 12 
3  DATA ANALYSIS AND RESULTS....................................................... 13 
  3.1 Functional Groups……………………………………………..... 13 
  3.2 Random Forest and PCA………………………………………... 14 
  3.3 Regression Modeling and Lasso Technique…………………….. 15 
  3.4 Data Analysis: t-test and Heat Map……………………………... 23 
4  CONCLUSION…………………............................................................. 25 
REFERENCES................................................................................................................. 26  
 
v 
 
APPENDIX Page 
 A MATLAB CODE FOR DATA FILTERING……………….................. 30 
 B R CODE FOR PROBABIBILISTIC QUOTIENT NORMALIZATION 
(PQN)…………………………………………………………………... 40 
   
 C R CODE FOR T-TEST AND HEAT MAP…………………………..... 43   
BIOGRAPHICAL SKETCH .......................................................................................... 49   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
LIST OF TABLES 
Table                     Page 
1. Demographics of Subjects ……………………………………………………. 5 
2. Top Analytes from Estrogen Regression Model ……………………………… 17 
3. Top Analytes from Progesterone Regression Model………………………….. 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF FIGURES 
Figure                     Page 
1. Urine Degradation Study ……………………………………………………… 7 
2. Chromatogram of Urine Sample ……………………………………………… 8 
3. Volatile Analyte Classification………………………………………………… 13 
4. Balanced PCA of 7 Subjects …………………………………………………... 15 
5. Estrogen Predicted Model vs. Estrogen Literature Curve …………………….. 18 
6. Progesterone Predicted Model vs. Progesterone Literature Curve…………..… 20 
7. Estrogen Model Predictive Expression ……………………………………….. 20 
8. Progesterone Model Predictive Expression……………………………………. 20 
9. Estrogen Residuals Normal Quantile Plot ……………….……………………. 21 
10. Progesterone Residuals Normal Quantile Plot…………………………………. 21 
11. Estrogen Residuals vs. Days ………………………………………………….. 22 
12. Progesterone Residuals vs. Days………………………………………………. 22 
13. Significant Compounds from t-test Analysis…………………………………… 24 
 
 
 
 
 
 
 
 
 
 
 
1 
 
CHAPTER 1 
INTRODUCTION/BACKGROUND LITERATURE 
In the United States, one out of ten women 1.6 million women (ages 15-44) has 
complications with fertility, affecting approximately 1.6 million individuals annually [1]. 
In 2012, the estimated market for individuals seeking fertility services reached $3.5 
billion [2]. Fertility, or the natural ability to reproduce, directly correlates to hormone 
production. The reproductive health of a woman is indicated by hormones such as 
estrogen, progesterone, anti-mullerian hormone (AMH), follicle stimulating hormone 
(FSH), and luteinizing hormone (LH) [3-5]. During a woman’s 28-day menstrual cycle, 
hormone levels naturally change. These hormone-related changes affect the release of an 
egg from an ovary, known as ovulation. During this process, fluctuations in hormone 
levels, which are indicative of ovulation, are present in metabolic shifts within biological 
fluids [6]. Current methods of testing ovulation include clinical and at-home diagnostics 
such as: blood tests, basal body temperature monitoring, and fertility kits [7-9], evaluated 
at a single time point. A woman’s reproductive health, however, changes with time [10]. 
These available methods lack the ability to quantify metabolic alterations in hormones 
across years. Understanding the long-term ovulatory and physiological health of a women 
can give insight into trends in reproductive health over time. Thus, a critical need exists 
to measure reproductive hormones and their corresponding metabolites in real-time 
across a woman’s reproductive years. 
Metabolic profiling of biological samples has recently shown promise of 
developing into an accurate and real-time monitoring technique to diagnose hormone-
related diseases, such as diabetes, cancer, and neurological disorders [11-15]. Hormones 
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are part of the reproductive metabolic pathway and are directly correlated to metabolites 
[16]. Metabolite evaluation in biological samples has therefore emerged as a promising 
way to indicate hormone levels in real-time due to being readily available in biological 
samples [16]. An example of this can be found in the hormone, estrogen, where 
metabolic by-products result when estrogen is broken down from the parent estrogens of 
estrone and estradiol. During this reaction, oxidation of estrone and estradiol occur at the 
C-2 or C-4 positions to produce catechol estrogen metabolites, which include 2-
hydroxyestrone, 2-hydroxyestradiol, and 4-hydroxyestrone [16]. Likewise, progesterone 
can be reduced to 5α-pregnan-3, 20-dione and 3α-hydroxy-5α-pregnan-20-one 
metabolites [17]. Specific volatiles released from these metabolites can be traced back to 
the parent hormones. Volatiles consist of low molecular weight compounds, which are 
usually less than 400 g/mol [18] and readily become vapors or gases at room temperature. 
These vapors, or volatile organic compounds (VOCs), can be collected in the headspace 
of, or air above, biological samples [19]. Current studies show VOCs eluded from within 
different biological samples, including blood, saliva, and urine [20-23]. In addition, 
VOCs have been studied across a variety of fields, including toxicology, oncology, and 
neurology [13-15], for applications in personalized diagnostics. Research utilizing VOCs 
to monitor reproductive hormones in real-time, however, is limited. Investigations have 
shown gas chromatography-mass spectrometry (GC-MS) to be a reliable method of 
detecting VOCs at physiological levels. With high specificity at lower limits of detection 
[24], GC-MS can distinguish different VOCs within complex biological samples. To gain 
even better resolution, two-dimensional gas chromatography-time-of-flight mass 
spectrometry (GC x GC-TOFMS) differentiates structurally similar compounds by 
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preventing peaks from co-eluding [25]. Furthermore, solid-phase microextraction 
(SPME) reduces interference from higher molecular weight compounds, therefore, 
enabling volatile binding between the molecular weights of 40-275, promoting a wider 
range of volatile collection [25]. Thus, GC x GC-TOFMS combined with SPME provides 
a simple and rapid extraction technique to collect VOCs, and delivers better 
reproducibility, detection, and separation of VOCs from complex biological sample 
matrices [25].  
In this study, we employed GC x GC-TOFMS with SPME to analyze the VOCs in 
the urine samples of ten healthy women across a 28-day cycle. The aim of this study was 
to evaluate metabolic shifts of VOCs as they relate to fertility hormones across a healthy 
woman’s menstrual cycle. Results indicate a significant shift in VOCs correlating to the 
estrogen hormone during ovulation. Furthermore, VOCs from the urine samples consist 
of different functional groups, including alcohols, aldehydes, amides, amines, aromatics, 
carboxylic acids, ethers, hydrocarbons, ketones, and thiols. Further studies will need to 
investigate the potential of metabolic changes in volatile hormone expression for use as 
an early indicator of declining fertility. Through this work, women may one day be able 
to monitor their reproductive health in real-time as they age.  
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CHAPTER 2 
METHODOLOGY 
2.1 Sample Collection and Preparation 
The sample collection protocol was approved by the Institutional Review Board at 
Arizona State University. Urine samples were obtained from ten healthy women of 
Asian, African, Caucasian, and Hispanic origin in the age group of 18-28 years (Table 1). 
Women included in this study were not taking any medication known to affect hormonal 
balance, including birth control. The urine samples were acquired daily in 20 mL glass 
vials, for 30 consecutive days. All sample collection was completed with a 1-month time 
frame. All samples were collected in the morning between 8 am and 12 pm. The subjects 
did not eat for 2 hours, prior to collection. A standard sterile collection procedure was 
followed [26]. Prior to collection, subjects used alcohol wipes to clean the area of 
collection. The samples were collected mid-stream during urination. Urine samples were 
capped and remained at 4°C for up to an hour. Within one hour of sample collection, the 
samples were aliquoted into 1.5mL cryogenic vials (VWR International, Radnor, PA) for 
storage in a -80°C freezer for one year, prior to testing.   
In preparation for sample testing, the 10-mL VOC-free vials and PTFE/silicone 
caps were baked at 100°C for 12 hours in an oven to reduce contamination and variation 
across the vials and caps (Supelco/Sigma-Aldrich, St. Louis, MO). One hour before 
testing, samples, vials, and caps were brought to room temperature. The samples were 
inverted to mix, and 1 mL of sample was transferred to vials and securely closed with a 
cap. The sample vials were placed into a chilled tray held at 4°C until tested. A Gerstel 
MultiPurpose Sampler (MPS; Gerstel, Mülheim an der Ruhr, Germany) was used for 
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sample preparation, transport, and extraction. Samples were incubated at 60°C with 
agitation at 250 rpm for 5 minutes. The volatile metabolites of urine were sampled from 
the headspace by SPME, using a 50/30 μm divinylbenzene/carboxen/ 
polydimethylsiloxane (DVB/CAR/PDMS; Supelco/Sigma-Aldrich) coated fiber. Prior to 
each sample extraction, fiber bake-out was performed for 10 min at 270°C. Sample 
extraction was performed at 60°C with agitation at 250 rpm for 60 min. Subsequently, the 
fiber was injected into the GC inlet for 5 min at 250°C. 
Table 1. Demographics of Subjects. The table shows the age, ethnicity, height, weight, 
and ovulation confirmation by ovulation kit of the 10 subjects. 
 
Subject 
No 
Age 
(years) Ethnicity Height Weight (lbs) 
Ovulation 
Confirmation 
1 24 Hispanic 5'4" 122 Yes 
2 21 Hispanic 5'3" 110 Yes 
3 19 Asian 5'6" 150 Yes 
4 21 
African 
American 5'1" 105 Yes 
5 20 Caucasian 5'5" 109 Yes 
6 24 Asian 5'9" 121 Yes 
7 19 Hispanic 5'0" 100 Yes 
8 18 Caucasian 5'8" 127 No 
9 18 Asian 5'4" 130 No 
10 27 Caucasian 5'5" 150 No 
 
 
2.2 Method Optimization 
Test conditions were optimized prior to running the study. Selection criteria was 
based on the maximum number of VOCs that could be collected. The optimal number of 
analytes collected by SPME were evaluated through sample volume and extraction time 
measurements. Sample volume was tested at 500 µL, 1 mL, 1.5 mL, and 2 mL and 
analyzed by GC x GC-TOFMS three times at each sample volume. The average number 
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of analytes, with less than 15% deviation, collected in the headspace across the three runs 
was 320 at 500 µL, 394 at 1 mL, 438 at 1.5 mL, and 470 at 2 mL. The sample volume of 
1 mL was selected to maximize the number of volatiles collected while keeping the 
sample volume consistent across runs, with a limited sample amount.  
Extraction time was tested at 30, 45, and 60 min, using 1mL urine samples. 
Preliminary studies were tested using a 65 µm CAR/PDMS fiber within a 10-mL 
headspace vial. Extraction was performed by SPME in the headspace and analyzed by 
GC x GC-TOFMS three times consecutively. The average number of analytes, with less 
than 10% deviation, collected across the three runs was 626 for 30 min, 689 for 45 min, 
and 819 for 60 min. The extraction time of 60 min was therefore selected to maximize the 
number of volatiles collected, and used in the final testing conditions, as indicated above. 
Furthermore, a 50/30 μm DVB/CAR/PDMS coated fiber was chosen due to the wide 
range (molecular weight of 40-275) of volatiles and semi-volatiles collected.  
Degradation of samples was tested by running 10 samples consecutively from one 
urine collection in a 4°C chilled tray. The signal-to-noise ratio of the compound 2-
heptanone across the 10 samples is shown in Figure 1 as an example compound that did 
not degrade over the 12.6 hours the 10 samples ran. In addition, no significant 
degradation was found in all the other compounds in the samples over time. 
 
 
 
 
 
 
7 
 
 
Figure 1. Urine Degradation Study. The analyte 2-heptanone is shown as an example 
compound, which did not degrade over 10 samples, as a result of the samples being in a 
4°C chilled tray.  
 
2.3 Instrumentation 
Calibration of the mass spectrometer was executed daily to maintain instrument 
performance, which included ion optic and source focusing, acquisition system 
adjustments, mass calibration, tune checks, and leak checks. All analyses of urine 
samples were performed by GC x GC-TOFMS [27]. The instrument was fitted with a 
two-dimensional column set, joined together by a press-fit connection. The first column 
consisted of an Rxi-624Sil MS (60 m x 250 µm x 1.4 µm [length x internal diameter x 
film thickness]; Restek, Bellefonte, PA). The second column consisted of a Stabilwax (1 
m x 250 µm x 0.5 µm; Restek). Each of the two columns were heated independently. The 
first column in the primary oven was heated with an initial temperature of 50°C, held for 
2 min. The oven was ramped at 5°C/min to 225°C and held for 2 min for temperature 
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stability. Subsequently, the oven was ramped at 30°C/min to 230°C and held for 30 min 
for post-column bake-out. The second column was heated with a +5°C offset relative to 
the primary oven. A quad-jet modulator was used with 2 s modulation periods (0.5 s hot, 
0.5 s cold pulses) and a +15°C offset relative to the secondary oven. The helium carrier 
gas flow rate was 2 mL/min. Mass spectra were acquired at 100 Hz over a range of m/z = 
35-550. Data acquisition was captured by ChromaTOF software, Version 4.60.8.0 (Leco 
Corp., St. Joseph, MI) [27]. A resulting chromatogram of one urine sample of a single 
subject on a single day is shown in Figure 2. 
 
Figure 2. Chromatogram of Urine Sample. The resulting chromatogram of a urine 
sample of one of the subjects is shown. The compound 4-heptanone has been identified as 
one of the compounds in the headspace of the urine sample. 
 
 
2.4 Data Alignment and Normalization 
A Kovats index (KI) standard mix of alkanes was used to identify retention times 
at the beginning, middle, and end of the GC x GC-TOFMS runs. KI is used to confirm 
compounds eluded at retention times within known values and can be used as a reference 
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from instrument to instrument as it is independent of the system [28]. Retention indexes 
were also compared to ensure that the equipment did not drift over time. Data processing 
and chromatographic alignment were completed using the Statistical Compare package of 
ChromaTOF software, Version 4.60.8.0. For a peak to be identified as the same 
compounds across chromatograms, both the retention times and the mass spectra had to 
meet minimum match criteria. The first-dimension retention time could not vary more 
than 2 s from chromatogram-to-chromatogram, and the second-dimension retention time 
could not vary more than 0.2 s from chromatogram-to-chromatogram. The mass spectrum 
for aligned peaks had to meet a minimum match threshold of 600. The baseline was fixed 
to be through the middle of the noise, and the signal-to-noise (S/N) cutoff for peak 
finding was set to 50 for a minimum of two apexing masses. Peaks were putatively 
identified using the National Institute of Standards and Technology (NIST) Mass Spectral 
Library and published retention time data. All peaks eluded during blank runs and known 
contaminants were excluded from data analysis.   
Multiple normalization and alignment analysis were performed on the raw data 
prior to statistical analysis. Relative abundance of the analytes was normalized across 
chromatograms using the Probabilistic Quotient Normalization (PQN) method [29]. Data 
normalization was performed in R, Version 1.0.136 [27] prior to any data analysis. 
Ovulation across all subjects was tested using commercially available ovulation kits 
(Clearblue). Ovulation is a well-known indicator of healthy fertility in women [30]. The 
first day of menses was reported by each subject. The ovulation day, signified by an 
increase in the luteinizing hormone (LH), was confirmed in 7 out of the 10 subjects. All 7 
subjects were aligned, so ovulation day corresponded with day 14 of the menstrual cycle. 
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The data obtained from all 10 subjects were used in the functional group classification. 
The data acquired from 7 out of the 10 subjects were used for all data analysis, where 
ovulation was validated. 
2.5 Data Analysis: Random Forest and PCA 
 After the data was processed, filtered, and normalized, the remaining compounds 
were imported into R for further analysis. Unsupervised learning principal component 
analysis (PCA) of the compounds showed there was no pattern in the data between four 
baseline estrogen days and four peak days, across the 7 subjects. Thus, the supervised 
learning technique of random forest was employed to discover the discriminatory 
analytes that differentiated between estrogen peak days and estrogen baseline days for the 
7 subjects, where ovulation was confirmed [31]. The code used the function 
“randomForest” from the “Random Forest” package in R. The random forest was run 100 
times and outputted the top discriminatory analytes with the least mean decrease in 
accuracy from the model that drove the classification between baseline estrogen days and 
peak days. After supervised learning by random forest, PCA was performed on the top 
discriminatory variables [32] in R with the function “prcomp”.  The function “ggplot” 
was used to plot the first principal component to account for the largest possible variance 
in the variables, and the second principal component to account for the second largest 
possible variance in the variables. Data analysis was performed in R, Version 1.0.136. 
2.6 Data Analysis: Regression Model and Lasso Technique 
The data was imported into JMP for regression model analysis. A total of 935 
compounds were included in the regression model. The “Fit Model” menu was utilized to 
calculate the forward-stepwise regression model with Akaike Information Criterion 
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Corrected (AICc) [33, 34]. The model was employed to identify potential biomarkers 
from the biological samples, as per the estrogen and progesterone literature curves. To 
prevent the model from overfitting and reduce the number of compounds, the adaptive 
Lasso technique with 5-fold cross-validation was performed in JMP with the “Fit Model” 
menu [35]. The data set was split into 5 different sets, with the Lasso technique using 
80% of the data to train the model and 20% of the data to test the model. Significant 
compounds (p<0.001) were retained in the final models. Data analysis was performed in 
JMP Pro, Version 13.1.0. Regression model calculations used 7 out of the 10 subjects, 
where ovulation was verified. 
2.7 Data Analysis: t-test and Heat Map 
Data used in this analysis was evaluated and determined to be accurate for 
compound significance. The data set was imported into R for analysis. R was used to 
filter the data set, so the core compounds that appeared in at least half the subjects (3 out 
of 7 subjects) in at least half the days (14 out of 28 days) were utilized in the data 
analysis (Appendix C). The missing data values were converted from 0 to NA (not 
applicable) in the data set and were not used in the analysis. The pairwise Student’s t-test 
was performed on the median of 5 baseline estrogen days vs. the median of 5 peak 
estrogen days [36]. The function “t.test” was employed in R for the pairwise Student’s t-
test. The resulting significant compounds (p<0.05) were plotted in a heat map to look at 
the signals of each compound across the menstrual cycle. The “heatmap” function was 
used to plot the significant compounds in a heatmap. Data analysis was performed in R, 
Version 1.0.136. 
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2.8 Compound Validation and Quality of Data 
Compounds, selected using the t-test, were validated through a confirmation of 
the retention indices as shown in data produced from the GC x GC-TOFMS. The 
presence of retention indices confirms retention times as they relate the identified 
compounds to the known compounds. The NIST database clarifies the retention time in 
the GC x GC-TOFMS data. Unconfirmed compounds result in a lower quality analysis. 
The quality of the compound identifications was assigned (levels 1-4) following 
published guidelines [28]. Level 2 compounds were categorized based on greater than or 
equal to 60% mass spectral match, utilizing forward searches of the NIST mass spectral 
library. In addition, level 2 compounds had validated retention time data with 
experimentally-determined retention indices that are consistent with the mid-polar Rxi-
624Sil stationary phase. Level 2 was the highest classification in this study. Level 3 
compounds were classified on greater than or equal to 60% mass spectral match to the 
NIST library. Level 4 compounds have mass spectral matches less than or equal to 60%, 
but can still be determined from mass spectral data. 
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CHAPTER 3 
DATA ANALYSIS AND RESULTS 
3.1 Functional Groups 
With the optimized parameters, the functional groups resulting from the volatiles 
expressed in all the urine samples of the 10 subjects were analyzed (Figure 3). Volatile 
analytes were classified as core, rare, or accessory metabolites according to the following 
criteria: 
Core: Identified in all 10 subjects; 
Rare: Identified in only 1 subject; 
Accessory: Identified in 2-9 subjects. 
Functional group analysis shows there are more core analytes (498) associated between 
all the samples than rare analytes (30). The total number of accessory analytes was 451.  
 
Figure 3. Volatile Analyte Classification. Analytes were classified as core, accessory, or 
rare, and each one was assigned to a functional group (ACI = Acids; ALC = Alcohols; 
ALD = Aldehydes; AMI = Amides; AMN = Amines; ETH = Ethers; FUNC AROM = 
Functionalized Aromatics; HC = Saturated/Unsaturated Hydrocarbons; HET AROM = 
Heteroaromatics; KET = Ketones; OTH = OTHER; THI = Thiols). 
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3.2 Random Forest and PCA 
This model was not utilized in the final selection of compounds due to the fact 
that continued analysis of data proved this method to be biased. It was discovered that the 
model had data values of 0 for missing data, which significantly biased the model. Future 
studies simplified the model in terms of high and low abundance and corrected the values 
from 0 to “NA”. To find particular analytes correlated with estrogen baseline days and 
estrogen peak days per the literature curve, random forest was employed to discover the 
top discriminatory analytes from the 7 subjects, where ovulation was confirmed. Using 
balanced data of 4 baseline estrogen days and 4 peak estrogen days across all 7 subjects, 
the top 10 discriminatory analytes from random forest were 1,3,5-Cycloheptatriene, 
3,7,7-trimethyl, 1-Butene, 4-isothiocyanato-1-(methylthio), 2,3-Pentanedione, 4-methyl, 
2-Butenal, 2-Butenal, (E), 2-Hexanone, 4-Acetyl-1-methylcyclohexene, Allyl 
Isothiocyanate, Benzyl 4-nitrophenyl carbonate, and Cyclobutylamine. PCA was 
performed on the 10 resulting analytes to determine the first principal component and 
second principal component (Figure 4). The first principal component accounted for 
37.4% of the variance, and the second principal component accounted for 21.4% of the 
variance. From the PCA, the baseline estrogen days cluster together, and the peak 
estrogen days cluster together. Peak estrogen days correspond with ovulation, so a 
distinct difference can be seen between the peak estrogen days and the baseline estrogen 
days. It was discovered the data set had values of 0 for missing data, which significantly 
skewed the model. Thus, random forest and PCA was not used in the final selection of 
compounds. Future studies simplified the model in terms of high and low abundance, 
thus, removing any time dependence. 
15 
 
 
Figure 4. Balanced PCA of 7 Subjects. The PCA of the 7 subjects shows a distinct 
separation between baseline estrogen days and peak estrogen days. The first principal 
component accounts for 37.4% of the variance, and the second principal component 
accounts for 21.4% of the variance. This data was later refuted and proven to be invalid. 
 
3.3 Regression Modeling and Lasso Technique 
This model was not utilized in the final selection of compounds due to the fact 
that continued analysis of the time dependency proved this method to be an invalid 
approach. Future studies simplified the model in terms of high and low abundance, 
removing any time dependence and correcting the values from 0 to “NA”. To further 
investigate the particular analytes correlated with the estrogen and progesterone literature 
curves across a woman’s menstrual cycle, forward step-wise regression with AICc was 
used. A total of 19 of 935 analytes were found to be significant (p<0.001) in the estrogen 
regression model, and a total of 18 of 935 analytes were found to be significant (p<0.001) 
in the progesterone regression model. The R2 value of both models were 0.999. In order 
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to prevent the data from being overfit, adaptive Lasso technique was performed. Further 
analysis using the adaptive Lasso technique with 5-fold cross-validation reduced the 
significant analytes down to 8 analytes for the estrogen model and down to 9 analytes for 
the progesterone model. For each hormone analysis, the model with the least out-of-
sample mean squared error of the 5 different train/test sets was selected as the predictive 
model. Model regression showed the predictive model of estrogen to be a linear 
combination of 8 analytes (Table 2), which strongly fits the estrogen curve as found in 
literature (Figure 5). Similarly, the model regression showed the predictive model of 
progesterone to be a linear combination of 9 analytes (Table 3), which strongly fits the 
progesterone curve as found in literature (Figure 6). The retention indices (Table 2, Table 
3) were only able to be calculated for the analytes that had a retention time between the 
retention times of the KI standard mix. The analyte 2-furanmethanol, 5-
ethenyltetrahydro-α,α,5-trimethyl-,cis- was common across estrogen and progesterone 
models. The predicted expression of the estrogen model is shown in Figure 7, and the 
predicted expression of the progesterone model is shown in Figure 8. Checking the 
assumptions of the model, the data was normal (Figure 9, Figure 10). Furthermore, the 
residual estrogen (Figure 11) and residual progesterone analysis (Figure 12) vs. menstrual 
cycle days show that no time dependence exists in the models. However, this was 
disputed and later removed in the study. It was also discovered that the model had data 
values of 0 for missing data, which significantly biased the model.  
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Table 2. Top Analytes from Estrogen Regression Model. Key analytes identified by the 
forward stepwise estrogen regression model with AICc and adaptive Lasso with 5-fold 
cross-validation. The first and second dimension retention times of each analyte from the 
GC x GC-TOFMS are shown. The retention indices shown were calculated for the 
analytes that had a retention time between the retentions time of the KI standard mix. 
Later refuted and proven to be invalid. 
 
No. Analyte First Dimension 
Retention Time (s) 
Second Dimension 
Retention Time (s) 
Retention 
Index 
1 1-Tetrazol-2-
ylethanone 
360 0.67 N/A 
2 2-Furanmethanol, 5-
ethenyltetrahydro-
α,α,5-trimethyl-,cis- 
1580 0.92 1099 
3 3-Buten-2-ol, 3-
methyl- 
704 0.83 N/A 
4 3-Hexen-1-ol, 
acetate,(E)- 
1570 0.89 1094 
5 4-Octanone 1214 0.77 923 
6 5-Ethyl-1-nonene 2108 0.68 N/A 
7 Acetone 346 0.79 N/A 
8 Decane,2,6,8-
trimethyl- 
1434 0.65 1029 
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Figure 5. Estrogen Predicted Model vs. Estrogen Literature Curve. The estrogen 
predicted model vs. the estrogen literature curve is shown across a healthy woman’s 
menstrual cycle. Later refuted and proven to be invalid. 
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Table 3. Top Analytes from Progesterone Regression Model. Key analytes identified by 
the forward stepwise progesterone regression model with AICc and adaptive Lasso with 
5-fold validation. The first and second dimension retention times of each analyte from the 
GC x GC-TOFMS are shown. Later refuted and proven to be invalid. 
No. Analyte First 
Dimension 
Retention 
Time (s) 
Second 
Dimension 
Retention 
Time (s) 
Retention 
Index 
1 2-Furanmethanol, 5-
ethenyltetrahydro-α,α,5-
trimethyl-,cis- 
1580 0.92 1099 
2 2-Heptanone, 6-methyl-6-[3-
methyl-3-(1-methylethenyl)-1-
cyclopropen-1-yl]- 
2472 0.94 N/A 
3 2H-Pyran-2-one, tetrahydro-4-
(2-methyl-1-propen-3-yl) 
1962 1.1 N/A 
4 4,4-Dimethyl-1-hexene 1304 0.87 966 
5 Cis-Verbenol- 1712 1.08 1163 
6 Cyclohexene, 3-(1,5-dimethyl-4-
hexenyl)-6-methylene-, [S-R*, 
S*)]- 
2314 0.86 N/A 
7 Isopropylcyclobutane 2342 1.2 N/A 
8 Pentanal, 2,4-dimethyl- 1416 0.79 1020 
9 Undecanal, 2-methyl- 1874 0.78 N/A 
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Figure 6. Progesterone Predicted Model vs. Progesterone Literature Curve. The 
progesterone predicted model vs. the progesterone literature curve is shown across a 
healthy woman’s menstrual cycle. Later refuted and proven to be invalid. 
 
y = 0.933 + 0.098*[1]– 0.295*[2] – 0.123*[3] + 0.035*[4] + 0.063*[5] – 0.211*[6] + 
0.354*[7] – 0.052*[8] 
Figure 7. Estrogen Model Predictive Expression. Predictive model expression of the 
estrogen model is shown with the corresponding analytes in Table 2 ([1] in the equation 
refers to Analyte No.1 in Table 2). Later refuted and proven to be invalid. 
 
y = 0.333 – 0.040*[1]– 0.139*[2] + 0.212*[3] + 0.212*[4] + 0.051*[5] – 0.259*[6] + 
0.326*[7] – 0.062*[8] – 0.117*[9] 
Figure 8. Progesterone Model Predictive Expression. Predictive model expression of the 
progesterone model with the corresponding analytes in Table 3 ([1] in the equation 
refers to Analyte No.1 in Table 3). Later refuted and proven to be invalid. 
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Figure 9. Estrogen Residuals Normal Quantile Plot. Normal quantile plot of the estrogen 
residuals shows the data to be normal. 
 
 
Figure 10. Progesterone Residuals Normal Quantile Plot. Normal quantile plot of the 
progesterone residuals shows the data to be normal. 
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Figure 11. Estrogen Residuals vs. Days. The estrogen residuals plotted vs. days shows 
there is no time trend in the data. Later refuted and proven to be invalid. 
 
 
Figure 12. Progesterone Residuals vs. Days. The progesterone residuals plotted vs. days 
shows there is no time trend in the data. Later refuted and proven to be invalid. 
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3.4 Data Analysis: t-test and Heat Map 
From the data filtering, using the core compounds in half of the subjects in half of 
the days, 935 compounds were reduced to 347 compounds. The Student’s t-test was 
performed on the median of 5 baseline estrogen days vs. the median of 5 peak estrogen 
days resulted in 10 significant compounds (Figure 13). These 10 compounds indicated a 
significant difference between the baseline estrogen days and peak estrogen days, which 
could help in the predication of ovulation. A heat map of the 10 compounds shows the 
signal of the compounds across the menstrual cycle (Figure 13). The compound, 3-Octen-
2-one, (E), seemed to show a signal around the time of ovulation, and it was validated by 
the retention index. Ketones were the chemical class that appeared the most number of 
times (3) from the 10 compounds.  
From the Student’s t-test, key compounds were discovered, which correlate to the 
fertility hormone of estrogen a woman’s menstrual cycle. Future tests involve validating 
the 10 significant compounds with independent data sets from other subjects. The 
independent data sets will seek to test the robustness of the compounds. Further 
investigations will seek to confirm if the analytes found are caused by the hormones of 
estrogen. In the future, quantification of the fertility hormones could be predicted, using 
this model, which could be used to identify declining fertility in women. 
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Figure 13. Significant Compounds from t-test Analysis. (a) The heat map of the 10 
significant compounds from the t-test analysis is shown. (b) The 10 significant 
compounds and their mass, ID level, chemical class, first dimension retention time (1tR), 
second dimension retention time (2tR), and retention index (RI) are displayed (For 
chemical class: ALD = Aldehydes; FUNC AROM = Functionalized Aromatics; HC = 
Saturated/Unsaturated Hydrocarbons; KET = Ketones; OTH = OTHER). (c) One of the 
10 significant compounds, 3-Octen-2-one, (E), and the plot of the relative abundance of 
the 7 subjects across the menstrual cycle are shown. Baseline estrogen days are marked 
in blue and peak estrogen days are marked in red. (d) Plot of baseline estrogen days vs 
peak days for 3-Octen-2-one, (E) shows a significant difference between the two.  
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CHAPTER 4 
CONCLUSION 
An analytical method was established to discover a more complete representation 
of the VOCs present in the urine samples of 10 healthy women. A total of 935 different 
analytes were identified in the urine samples. The t-test and heat map show there are 10 
key analytes within a woman’s menstrual cycle that can track the fertility hormone 
estrogen. From the functional group comparison, core common analytes were found to be 
shared across all the subjects. Through this study, we have identified potential volatile 
biomarkers that show statistical significance in correlation to hormonal changes in 
healthy women. Future research will aim to validate these biomarkers as an early 
expression of declining fertility in women. 
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APPENDIX A 
MATLAB CODE FOR DATA FILTERING 
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%% Preliminary 
% Start with a clean slate 
close all 
clear 
clc 
format compact 
  
%% Variables % 0 = no, 1 = yes 
plotBySubject = 0; 
plotByVOC = 0; 
plotByTotalArea = 0; 
writeGroups = 0 ; 
maxAbsence = 10000; 
maxArea = 0.000001; 
stepSize = 20; % VOCs per graph when plotBySubject == 1 
  
%% Functional Groups 
path = [pwd, '\Data\']; % set path to excel sheet 
files = dir([path, '*.xlsx']); 
funcGroups = {files.name}; 
  
%% Read data 
page = 1; % page of excel sheet to read 
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matrix = zeros(3,length(funcGroups)); 
ii = 1; 
close all 
[~, ~, raw]  = xlsread([path, funcGroups{ii}], page); % Read data from excel sheet 
raw = raw'; 
% Compartmentalize 
[rows, cols] = size(raw);                   % Size of excel sheet                       % Get names of 
VOCs 
subjectInfo = raw(1,2:end)';                % Get information on subject 
subject = zeros(length(subjectInfo)-100,3); % Allocate memory 
for i = 1 : length(subjectInfo)             % Run through subject info 
    str = subjectInfo{i,1};                 % Set info to string 
    C = strsplit(str,'_');                  % Split string based on _ 
    if strcmp(C{1}, 'Blank') == 1           % If Blank, do nothing 
    else 
        subject(i,1) = str2double(C{1});    % Set Subject ID to col 1 
        subject(i,2) = str2double(C{2});    % Set day to col 2 
        subject(i,3) = i;                   % Set index to col 3 
    end 
end 
  
%% Remove based on absences and max area 
[m, n] = size(raw); 
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for j = 2:m 
    for i = 2:n 
        if raw{j,i} == 0 
            raw{j,i} = NaN; 
        end 
    end 
end 
for j = m : -1 : 2 
    numOfNans = sum(isnan(cell2mat(raw(j,2:end)))); 
    tmp = max(cell2mat(raw(j,2:end))); 
    if numOfNans > maxAbsence || tmp < maxArea 
        raw(j,:) = []; 
    end 
end 
  
%% 
uni = unique(subject(:,1)); 
cnt = 1; 
superCell = cell(7,1); 
xAxis = cell(7,1); 
tmpMatrix = zeros(5,3); 
for i = 1 : length(uni) 
    for j = 1 : length(subject) 
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        if uni(i) == subject(j,1) 
            tmpMatrix(cnt,:) = subject(j,:); 
            cnt = cnt + 1; 
        end 
    end 
    [values, order] = sort(tmpMatrix(:,2)); 
    sortedMatrix = tmpMatrix(order,:); 
    sortedCell = raw(:,1); 
    cnt2 = 2; 
    for k = 1 : length(sortedMatrix) 
        index = sortedMatrix(k,3); 
        sortedCell(:,cnt2) = raw(:,index+1); 
        %         sortedCell(:,cnt2) = raw(:,3+5*index+3); 
        cnt2 = cnt2 + 1; 
    end 
    superCell{i} = sortedCell; 
    xAxis{i} = sortedMatrix(:,2); 
    clear tmpMatrix 
    clear sortedCell 
    clear sortedMatrix 
    cnt = 1; 
end 
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%% Filter for Core 
nameCell = superCell{i,1}(:,1); 
numSubjects = length(uni); 
barGraphMat = zeros(m,numSubjects+1); 
tempVect = 1:m; 
barGraphMat = [barGraphMat, tempVect']; 
for i = 1 : numSubjects 
    barGraphMat(1,i) = uni(i); 
    tmpMatrix = superCell{i,1}; 
    [m, n] = size(tmpMatrix); 
    for j = 2 : m 
        numOfNans = sum(isnan(cell2mat(tmpMatrix(j,2:end)))); 
        superCell{i,1}(j,n+1) = {n-1-numOfNans}; 
        barGraphMat(j,i) = n-1-numOfNans; 
    end 
end 
  
core = 0; 
accessory = 0; 
rare = 0; 
for j = m : -1 :2 
    idx = barGraphMat(j,1:numSubjects) == 0; 
    tempValue = numSubjects - sum(idx(:)); 
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    barGraphMat(j,numSubjects+1) = tempValue; 
    if tempValue == 7 
        core = core + 1; 
    elseif tempValue == 1 
        rare = rare + 1; 
        barGraphMat(j,:) = []; 
        nameCell(j,:) = []; 
    elseif tempValue == 0 
        display('empty???') 
        barGraphMat(j,:) = []; 
        nameCell(j,:) = []; 
    else 
        accessory = accessory + 1; 
        barGraphMat(j,:) = []; 
        nameCell(j,:) = []; 
    end 
end 
  
%% Analyze 
  
core = 0; 
accessory = 0; 
rare = 0; 
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[m2, ~] = size(barGraphMat); 
for j = m2 : -1 : 2 
    idx = barGraphMat(j,1:numSubjects) < 14; 
    tempValue = numSubjects - sum(idx(:)); 
    barGraphMat(j,numSubjects+1) = tempValue; 
    if tempValue > 3 
        core = core + 1; 
    elseif tempValue == 1 
        rare = rare + 1; 
        barGraphMat(j,:) = []; 
        nameCell(j,:) = []; 
    elseif tempValue == 0 
        display('empty???') 
        barGraphMat(j,:) = []; 
        nameCell(j,:) = []; 
    else 
        accessory = accessory + 1; 
        barGraphMat(j,:) = []; 
        nameCell(j,:) = []; 
    end 
end 
  
nameCell = [nameCell, num2cell(barGraphMat)]; 
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nameCell{1,9} = 'Over 14'; 
nameCell{1,10} = 'Row in Raw'; 
matrix(1,ii) = core; 
matrix(2,ii) = accessory; 
matrix(3,ii) = rare; 
xlswrite([path, funcGroups{ii}(1:end-5),'_updated1.xlsx'], nameCell) 
  
%% Add data to matrix from raw 
concatCell = superCell{1}; 
for i = 2 : numSubjects 
    concatCell = [concatCell, superCell{i}(:,2:end)]; 
end 
  
nameCell2(1,:) = [nameCell(1,:), concatCell(1,:)]; 
[f, g] = size(nameCell); 
for i = 2 : f 
    nameCell2(i,:) = [nameCell(i,:), concatCell(nameCell{i,g},:)]; 
end 
xlswrite([path, funcGroups{ii}(1:end-5),'_updated2.xlsx'], nameCell2) 
  
%% Graph 
legendNames = cell(1, numSubjects); 
for i = 1 : length(funcGroups) 
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    legendNames{i} = funcGroups{i}(1:end-5); 
end 
% figure('units','normalized','outerposition',[0 0 1 1]); 
bar(matrix,'stacked') 
xt = get(gca, 'XTick'); 
set(gca, 'XTick', xt, 'XTickLabel', {'Core' 'Accessory' 'Rare'}) 
% legend(legendNames, 'Location','northwest','Orientation','horizontal') 
% legend(legendNames) 
ylabel('Number of Volatile Molecules') 
% ylim([0 550]) 
  
%% 
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APPENDIX B 
R CODE FOR PROBABIBILISTIC QUOTIENT NORMALIZATION (PQN) 
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## Function: Probabilistic Quotient Normalization ## 
PQN <- function (X) { 
   
  obs <- dim(X)[1]     #Define number of observations. 
  dimm <- dim(X)[2]     #Define number of variables (dimensions). 
   
  X[0==X] <- 1E-08     #Set zeroes to an arbitrarily small value. 
  normRef <- apply(X,2,function(x){median(x[x>1E-08])})     #Define reference 
spectrum as median for all analytes. 
   
  M <- matrix(rep(normRef, each=obs), ncol=length(normRef))     #Convert reference 
spectrum in matrix equivalent in size to data matrix. 
  Q <- X/M     #Divide the concentration of the analyte in each sample by the median 
value for each analyte. 
  Q[0.001 >= Q] <- NA      #Set very small values of "Q" equal to NA for elimination in a 
subsequent step.    
  for (i in 1:obs) { 
    X[i,] <- X[i,]/median(Q[i,], na.rm=TRUE)}     #Divide each analyte in a given sample 
by the median quotient in that sample. 
   
  X[1 >= X] <- 0     #Convert very small normalized values to 0. 
  return(matrix(X, nrow=obs, ncol=dimm)) 
} 
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PREP <- function (X) { 
  dimm <- dim(X)[1] #Define the number of variables (dimensions). 
  obs <- dim(X)[2] #Define the number of observations. 
  analyte.names <- X[,1] #Determine the analyte names. 
  X <- t(X[,-1]) #Transpose the data matrix without the first column. 
  colnames(X) <- analyte.names #Make the analyte names the names of matrix columns. 
  X[is.na(X)] <- 0 
  return(as.matrix(X)) 
} 
 
## Function: Data Matrix Final Transposition ## 
REMATRIX <- function (X) { 
  X <- t(X) #Transpose the data matrix without the first column. 
  X[0==X] <- NA 
  return(X)} 
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APPENDIX C 
R CODE FOR T-TEST AND HEAT MAP 
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# Load data 
d1 = 
read.csv('urine_data_normalized_7subjects_orderedformenstrualcycle_rev1_NA.csv', 
header=T, row.names=1) 
 
# Half the subjects across half the days 
compounds = c(3:length(colnames(d1))) 
f1 = sapply(colnames(d1)[compounds], function(c1) { tmp = sapply(1:28, function(x) { 
sum(is.na(d1[which(d1[,'Day.of.Menstrual.Cycle']==x),c1]))<=4 } ); 
return(sum(tmp)/length(tmp)) } ) 
f2 = names(which(f1>=0.5)) 
 
# Get sample information 
s1 = unique(d1[,'Day.of.Menstrual.Cycle']) 
n1 =  unique(d1[,'Subject.ID']) 
 
# Samples to median for T-test 
baseline = c(27,28,1,2,3) 
peak = c(12,13,14,15,16) 
#baseline = c(28,1,2) 
#peak = c(13,14,15) 
#baseline = c(1) 
#peak = c(14) 
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# For each compound comapre using T-test 
pdf('boxplot_p_m_2days_split.pdf') 
m1 = matrix(ncol=2,nrow=length(f2)) 
colnames(m1) = c('FC','P.value') 
rownames(m1) = f2 
for(c1 in f2) { 
    bsl1 = sapply(n1, function(x) { 
median(d1[intersect(which(d1[,'Day.of.Menstrual.Cycle'] %in% 
baseline),which(d1[,'Subject.ID']==x)),c1],na.rm=T) } ) 
    pk1 = sapply(n1, function(x) { 
median(d1[intersect(which(d1[,'Day.of.Menstrual.Cycle'] %in% 
peak),which(d1[,'Subject.ID']==x)),c1],na.rm=T) } ) 
    t1 = try(t.test(pk1,bsl1,paired=T)) 
    print(t1) 
    if(!class(t1)=='try-error') { 
        m1[c1,'FC'] = median(pk1,na.rm=T)/median(bsl1,na.rm=T) 
        m1[c1,'P.value'] = t1$p.value 
        if(t1$p.value<=0.05) { 
            boxplot(c(bsl1,pk1) ~ 
c(rep('Baseline',length(bsl1)),rep('Peak',length(pk1))),col=c(rgb(0,0,1,0.8),rgb(1,0,0,0.8)),
main=paste(c1,'; P-value =',signif(m1[c1,'P.value'],2),sep='')) 
        } 
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        #stripchart(c(bsl1,pk1) ~ c(rep('Baseline',length(bsl1)),rep('Peak',length(pk1))), 
vertical = TRUE, method = "jitter", add = TRUE, pch = 20, col = rgb(0,0,0,0.5)) 
    } 
} 
m2 = na.omit(m1) 
m2 = cbind(m2,Adj.P.value=p.adjust(m2[,'P.value'],method='BH')) 
write.csv(m2,'p_m_2days.csv') 
dev.off() 
 
# Volcano plot 
plot(log2(m2[,'FC']),-log10(m2[,'P.value']),col=rgb(1,0,0,0.5),pch=20) 
abline(h=-log10(0.05),lty=2) 
abline(v=c(-log2(2),log2(2)),lty=2) 
 
# Plot major players 
up = rownames(m2)[intersect(which(m2[,'FC']>1),which(m2[,'P.value']<=0.05))] 
down = rownames(m2)[intersect(which(m2[,'FC']<1),which(m2[,'P.value']<=0.05))] 
pdf('up_and_down_p_m_2days.pdf') 
for(i in c(up,down)) { 
    boxplot(as.numeric(d1[,i]) ~ 
addNA(as.numeric(d1[,'Day.of.Menstrual.Cycle'])),col=c(rep(rgb(0,0,1,0.8),3),rep('white'
,8),rep(rgb(1,0,0,0.8),5),rep('white',10),rep(rgb(0,0,1,0.8),3)),main=paste(i,'; P-value 
=',signif(m2[i,'P.value'],2),sep='')) 
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    stripchart(as.numeric(d1[,i]) ~ addNA(as.numeric(d1[,'Day.of.Menstrual.Cycle'])), 
vertical = TRUE, method = "jitter", add = TRUE, pch = 20, col = rgb(0,0,0,0.5)) 
} 
dev.off() 
 
# Matrix of median expression across participants for each compound 
tmp = sapply(f2, function(c1) { sapply(1:28, function(x) {  
median(d1[which(d1[,'Day.of.Menstrual.Cycle']==x),c1],na.rm=T) }) } ) 
tmp2 = sapply(colnames(tmp), function(x) { (tmp[,x] - median(tmp[,x], 
na.rm=T))/mad(tmp, na.rm=T) } ) 
 
library(gplots) 
pdf('heatmap.pdf') 
heatmap.2(t(as.matrix(tmp2[,c(up,down)])),trace='none',col=colorpanel(256,'blue','black',
'yellow'),Colv=F,Rowv=T,dendrogram='row',density.info='none') 
dev.off() 
 
 
 
library(gplots) 
m3 = t(sapply(1:length(unique(cut1)), function(x) { 
apply(tmp[,names(which(cut1==x))],1,mean,na.rm=T) })) 
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heatmap.2(as.matrix(m3),trace='none',col=colorpanel(256,'blue','black','yellow'),Colv=F,
Rowv=T,dendrogram='none',density.info='none') 
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